Bonvinal Injection (Ibandronate Sodium Monohydrate)

Adult dosage

Administer 3 mg intravenously every 3 months over 15 - 30 seconds.

This medication must be administered intravenously, and caution should be taken as administration into arteries or around veins may damage surrounding tissues. It should not be used in individuals allergic to this medication or its components. Additionally, it should not be administered to patients with hypocalcemia, a condition of low calcium levels in the blood. This medication may cause gastrointestinal adverse reactions such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, and constipation. Musculoskeletal symptoms such as musculoskeletal pain, joint pain, and myalgia have also been reported. In some patients, systemic and neurological adverse reactions may occur, such as flu-like symptoms, fatigue, headache, and rash. Rarely, severe allergic reactions such as skin allergy reactions, angioedema, and anaphylaxis may occur; if symptoms arise, immediate consultation with a healthcare professional is necessary. This medication may temporarily lower serum calcium levels, so treatment for hypocalcemia or bone and mineral metabolism disorders should be performed prior, and it is important to ensure adequate intake of calcium and vitamin D. Patients undergoing dental treatment or cancer patients may be at risk for osteonecrosis of the jaw, so oral examinations and preventive dental treatments are necessary before using this medication. Excessive dental treatment should be avoided while administering the medication, and if osteonecrosis of the jaw is suspected, consultation with a specialist is required. In some patients receiving this medication, fractures may occur in uncommon sites such as the femur, so if pain occurs in the thigh or groin area, an evaluation should be conducted. The safety in pregnant or breastfeeding women has not been established; therefore, its use is not recommended. This medication is not metabolized in the liver and is excreted through the kidneys; hence, patients with impaired kidney function need regular monitoring during treatment. In cases of overdose, kidney and liver function should be carefully monitored, and appropriate treatment should be provided if electrolyte imbalances such as hypocalcemia occur. This medication should not be mixed with calcium-containing solutions and must be administered exclusively via intravenous injection. After use, the injection needle and syringe should not be reused and must be disposed of safely.

Serious side effects

Urticaria, severe swelling (edema), angioedema, facial swelling/edema, anaphylactic reaction/shock, exacerbation of asthma, difficulty breathing, respiratory distress, severe allergic reactions, Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, severe skin adverse reactions, multiple organ failure, death, osteonecrosis (jaw osteonecrosis, external auditory canal osteonecrosis), acute renal failure, phlebitis/thrombophlebitis, severe bone, joint, and muscle pain, serious neurological

Mild side effects

• Gastritis
• diarrhea
• abdominal pain
• dyspepsia
• nausea
• constipation
• musculoskeletal pain
• joint pain
• myalgia
• flu-like illness

This medication should be stored in a sealed container to prevent air exposure and should be kept at room temperature between 1 to 30 degrees Celsius. This storage method helps maintain the effectiveness of the medication and prevents degradation.

Appearance

This is an injection in a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, with a single-use needle attached.

Package unit

3 ml x 1 vial